 Connection
Paul Bunn to Cisplatin
This is a "connection" page, showing publications Paul Bunn has written about Cisplatin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.111 |
|
|
|
-
Bunn PA. Platinums in lung cancer: sufficient or necessary? J Clin Oncol. 2005 May 01; 23(13):2882-3.
Score: 0.205
-
Bunn PA, Dimou A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. J Clin Oncol. 2018 09 01; 36(25):2571-2574.
Score: 0.130
-
Bunn PA. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol. 1989 Aug; 16(4 Suppl 6):10-21.
Score: 0.070
-
Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002 Sep 15; 20(18 Suppl):23S-33S.
Score: 0.043
-
Bunn PA. Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol. 2002 Sep 01; 20(17):3565-7.
Score: 0.043
-
Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
Score: 0.042
-
Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM, Bunn PA. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May; 8(5):1280-7.
Score: 0.042
-
Bunn PA, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001 Oct; 7(10):3239-50.
Score: 0.040
-
Bunn PA, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000 Apr; 117(4 Suppl 1):138S-143S.
Score: 0.036
-
Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3419-24.
Score: 0.035
-
Bunn PA. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):25-30.
Score: 0.034
-
Bunn PA, Kelly K. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-144-S12-148.
Score: 0.030
-
Bunn PA. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-153-S12-162.
Score: 0.030
-
Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 02; 104:45-51.
Score: 0.029
-
Bunn PA. Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Semin Oncol. 1996 Dec; 23(6 Suppl 15):9-15.
Score: 0.029
-
Bunn PA, Kelly K. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1996 Dec; 23(6 Suppl 16):11-5.
Score: 0.029
-
Bunn PA. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):18-25.
Score: 0.029
-
Bunn PA, Kelly KL. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60.
Score: 0.027
-
Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995 Jul; 13(7):1632-41.
Score: 0.026
-
Hazuka MB, Crowley JJ, Bunn PA, O'Rourke M, Braun TJ, Livingston RB. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J Clin Oncol. 1994 Sep; 12(9):1814-20.
Score: 0.025
-
Bunn P, Arriagada R, Choi N, Feld R, Gregor A, Jett J, Johnson B, Komaki R, Kristjansen P, Murray N, et al. Combined modality therapy in small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S25-8.
Score: 0.024
-
Bunn PA. Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol. 1992 Feb; 19(1 Suppl 2):1-11.
Score: 0.021
-
Hazuka MB, Bunn PA, Crowley J. Maximum tolerated dose for low-dose continuous infusion cisplatin. Int J Radiat Oncol Biol Phys. 1991 Aug; 21(3):869-70.
Score: 0.020
-
Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs. 2006 May; 24(3):213-21.
Score: 0.014
-
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 01; 24(13):2038-43.
Score: 0.014
-
Levenson RM, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD. Phase II trial of cisplatin in small cell carcinoma of the lung. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):905-7.
Score: 0.010
-
Kelly K, Lovato L, Bunn PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Cancer Res. 2001 Aug; 7(8):2325-9.
Score: 0.010
-
Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 01; 19(13):3210-8.
Score: 0.010
-
Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30.
Score: 0.007
-
Seifter EJ, Bunn PA, Cohen MH, Makuch RW, Dunnick NR, Javadpour N, Bensimon H, Eddy JL, Minna JD, Ihde DC. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol. 1986 Sep; 4(9):1365-73.
Score: 0.004
-
Batist G, Carney DN, Cowan KH, Veach SR, Gilliom M, Bunn PA, Ihde DC. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol. 1986 Jun; 4(6):982-6.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|